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INTRODUCTION
With improved methods of diagnosis and effective management
of chronic respiratory diseases in India, the number of patients
with end-stage respiratory disease who may require lung
transplantation for survival and/or long term quality of life is
likely to increase. We discuss the indications, management and
outcome of lung transplantation patients in the USA and, based on
our experience, give details of the requirements to start a successful
lung transplantation programme.
BURDEN OF RESPIRATORY DISEASES IN INDIA
Chronic respiratory diseases are on the rise in India, accounting
for approximately 9% of all deaths in 2005.1 Chronic obstructive
pulmonary disease (COPD) was the fourth leading cause of death
worldwide in 2001 and is expected to be the third leading cause of
death by 2020.2,3 Recent reviews of the epidemiology of COPD in
India report prevalence rates of 2%–22% (median 5%) in men and
1.2%–19% (median 2.7%) in women.4,5 A large multicentric study
sponsored by the Indian Council of Medical Research (ICMR)
estimated the prevalence of COPD to be 5% in men and 3.2% in
women. This extrapolates into a national burden of more than 8
million men and 5 million women.4,6 This figure is probably an
under-assessment as the true prevalence of these diseases in the
Indian subcontinent remains unknown because many patients
with COPD have never been diagnosed or have been misdiagnosed.
A study at the Hinduja Hospital of 2065 adults undergoing
spirometry as part of a routine health check revealed that a
staggering 96% of those with forced expiratory volume in 1
second (FEV1)/forced vital capacity (FVC) <70% had not been
correctly labelled and diagnosed as COPD.
By 2020 India alone will account for 18% of the 8.4 million
tobacco-related deaths globally.7 Thanks to greater availability of
computed tomography (CT) and fibreoptic bronchoscopy in India,
idiopathic pulmonary fibrosis (IPF) is now being diagnosed more
often.8 While estimates of the incidence and prevalence of IPF
in India are scarce, the clinical spectrum and presentation of this
disease appear to be similar to the clinical characteristics observed
in western countries.9 However, it has been noted that Indian
patients seem to develop the disease a decade earlier than their
counterparts in the West.10
Cystic fibrosis (CF), once thought to be primarily a disease of
western populations, is now being diagnosed in patients of Indian
origin who have emigrated to the USA and UK, with an estimated
frequency of 1:10 000 to 1:40 000.11–13 Although this is lower than
the estimated incidence of 1:2500 in Caucasians,14 the clinical
characteristics and disease progression of Indians diagnosed with
CF are similar. CF has also been observed in children living in
India. As the present prevalence rates remain unknown, paediatric
pulmonologists strongly suspect that CF cases in India are often
misdiagnosed and therefore underreported.11 It is anticipated that
as the quality of healthcare continues to improve in India, CF will
be diagnosed more often and survival of patients will improve, as
is the case in western countries. Consequently, an increasing
number of patients could live long enough to develop end-stage
lung disease.
LUNG TRANSPLANTATION: A TREATMENT OPTION?
One of the final treatment options in the algorithm for end-stage
lung disease from these conditions is lung transplantation. The
first human lung transplant was performed by Dr James Hardy at
the University of Mississippi, USA, in 1963. The patient survived
for 18 days before succumbing to complications.15 Twenty years
later, following improvements in immunosuppressive therapy
and surgical techniques, Joel Cooper and Alexander Patterson
(senior author of this article) from the University of Toronto
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reported the first long term survivor following lung transplanta-
tion.16–18 Since then, lung transplantation has become an accepted
and effective surgical treatment for a variety of end-stage lung
diseases.19 The International Society of Heart Lung Transplantation
(ISHLT), which has a global registry of all lung transplants
(www.ishlt.org/registries),20 has accrued data on 23 716 lung
recipients. Worldwide, more than 2000 lung transplants are
performed annually. About 50% of these transplants take place at
23 centres with an average activity of >30 transplants per year.21
Dr K. Cherian was the first in the Indian subcontinent to
perform a successful heart–lung transplant in Chennai in 1999.
Since then, he has performed 2 more successful heart–lung
transplants.22
WHO RECEIVES LUNG TRANSPLANTATION IN THE
WEST?
According to internationally recognized, standard criteria, lung
transplantation is offered to patients who have severe end-stage
lung disease despite maximally aggressive medical therapy, or to
patients for whom no effective medical therapies are available.
Prospective transplant patients have a limited life expectancy
(usually <2 years); it is anticipated that the transplant will provide
both a survival benefit and an improvement in the quality of life.
The patients should be capable of full rehabilitation post-
transplantation and must demonstrate an adequate psychosocial
profile. Absolute contraindications that preclude lung transplanta-
tion include extrapulmonary organ dysfunction, malignancy,
hepatitis B and C virus infections, and HIV infection. In addition,
current or recent history of smoking, alcoholism or drug abuse
precludes eligibility for transplant. Relative contraindications
include age >65 years, malnutrition, dependence on mechanical
ventilation, infectious diseases, obesity and severe osteoporosis.
The indications for lung transplantation can be divided into 4
main categories:
1. Obstructive lung disease: COPD, alpha-1 antitrypsin deficiency
emphysema, obliterative bronchiolitis
2. Suppurative lung disease: Cystic fibrosis, bronchiectasis
3. Interstitial lung disease: Idiopathic pulmonary fibrosis and
other causes such as sarcoidosis, connective tissue diseases,
etc.
4. Vascular: Pulmonary hypertension, Eisenmenger syndrome.
In the October 2007 ISHLT registry report, the main indications
for lung transplantation were COPD (37%), idiopathic pulmonary
fibrosis (19%), cystic fibrosis (16%), and alpha-1 antitrypsin
deficiency emphysema (8%). Figure 1 shows the indications of
adult lung transplantations over the time period 1990–2005 (Data
reprinted with permission from ISHLT).
WHO IS AN IDEAL LUNG DONOR?
The ideal lung donor (Table I) is one who has been pronounced
brain dead. From a medical standpoint, donors should be <55
years of age, have minimal to no smoking history, a clear chest
X-ray, no evidence of pulmonary infection on bronchoscopy and
sputum Gram stain, and a pO2 >300 mmHg on 100% FiO2 and
minimal positive end-expiratory pressure (PEEP, 5 cm H2O).
However, since the demand for donor lungs currently exceeds the
supply, these selection criteria are not rigidly followed. Favourable
outcomes using ‘extended donors’ have been reported from
several centres.23,24 However, the debate is ongoing among health
professionals and medical ethicists in many countries about the
use of non-heart-beating donors, who do not meet the criteria for
brain death but have irreversible brain injury.25 Living lung
donors have also been utilized in selected circumstances; this
option continues to be closely scrutinized from both the medical
and ethical standpoints.26,27
LUNG TRANSPLANTATION SURGERY: A SAFE
TECHNICAL PROCEDURE
Lung transplantation surgery has evolved into a safe technical
procedure over the past 2 decades. Advances in lung preservation,
immunosuppression and technical refinements have significantly
improved the outcomes following lung transplantation. Surgery
can be done with or without the use of cardiopulmonary bypass
depending on the indication for the operation and the experience
of the surgical team. The types of operations include:
1. Single lung transplant: This procedure can be done for most
indications (COPD, IPF) except for patients with suppurative
lung disease such as cystic fibrosis and bronchiectasis.
2. Bilateral lung transplant: This procedure is mandatory for
suppurative lung diseases (cystic fibrosis and bronchiectasis)
and can be done for all other indications.
3. Heart–lung transplant: This operation is reserved for patients
with end-stage cardiac and pulmonary disease (Eisenmenger
syndrome).28
Better overall survival rates in recipients of bilateral lung
transplants compared with those in patients who underwent single
lung transplants21,29 are largely responsible for the popularity of
bilateral lung transplants. The ISHLT registry data indicate that
63% of current transplants are bilateral.
In the largest single-centre experience from the Washington
University School of Medicine, St Louis, USA, the operative
mortality for adults undergoing lung transplantation was 7.1%
TABLE I. Criteria for an ideal lung donor
• Age <55 years
• Clear chest X-ray
• Smoking history <20 pack-year
• PaO2:FiO2 >300
• Sputum Gram stain free of organisms
• Bronchoscopy with clear secretions
• Absence of chest trauma
• ABO group compatability
FIG 1. Indications for adult lung transplantation (%)
CF cystic fibrosis IPF idiopathic pulmonary fibrosis
COPD chronic obstructive pulmonary disease
Alpha-1 alpha-1 antitrypsin deficiency emphysema
PPH primary pulmonary hypertension
(Reproduced with permission from Elsevier Limited)
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and the mortality for the paediatric population was 16.1%. The
most significant perioperative morbidity is primary graft failure
and the incidence was about 23% in their experience (Table II).
LUNG TRANSPLANT CERTIFICATION IN THE USA
Lung transplant surgeons are trained cardiothoracic surgeons who
require additional dedicated training for lung transplant surgery
during their cardiothoracic residency or an additional year of
training in the USA. The United Network for Organ Sharing
(UNOS), a central governing institution that regulates all transplant
activity in the USA, requires a lung transplant surgeon to have
experience with a minimum of 15 harvests and 15 implantations
at a UNOS-certified institution, before being certified to do lung
transplantation independently. UNOS requires a lung transplant
physician to be a pulmonologist with additional training in taking
care of at least 15 lung transplant patients. The pulmonologists
have to be involved in the pre-transplant assessment, perioperative
care and post-transplant management of these patients. They also
need to be involved with at least 3 donor management, organ
harvest and implantations. Medicare requirements for reimburse-
ment of procedural costs for an institution are that they perform a
minimum of 10 transplants with good outcomes on an annual basis
for hospital certification.
POST-LUNG TRANSPLANT IMMUNOSUPPRESSION
About half the patients receiving lung transplants receive
perioperative induction therapy. Use of polyclonal antilymphocyte/
antithymocyte globulins to prevent immune rejection of the graft
has declined in recent years, whereas the use of a monoclonal
interleukin-2 receptor antagonist had risen until 2005 but then
sustained a modest decrease. Maintenance immunosuppression
usually involves a 3-drug regimen: prednisone, a calcineurin inhibitor
(cyclosporin/tacrolimus) and cell cycle inhibitor (azathioprine/
mycophenolic acid). A patient for whom maintenance immuno-
suppression is initiated will remain on therapy for the rest of his/
TABLE II. Data of recipients transplanted at the Washington University, St Louis, USA programme
Item Paediatric (n=277) Adult (n=706)
Age (years)
Mean 10.7 (SD 6.4) 47.6 (SD 12.2)
Median 12.1 (IQR 5.4–15.8) 50.5 (IQR 38.9–57.6)
Gender (female) 156  (56.3) 357 (50.6)
Diagnosis
Emphysema 0 399 (56.5)
Cystic fibrosis 138 (49.8) 118 (16.7)
Pulmonary vascular disease 71 (25.6) 63 (8.9)
Other pulmonary disease 68 (24.6) 126 (17.8)
Type of transplantation
Bilateral 204 (73.6) 526 (74.5)
Single 8 (2.9) 176 (24.9)
Heart–lung 16 (5.8) 4 (0.6)
Bilateral lobar (living) 39 (14.1) 0
Bilateral lobar (cadaveric) 4 (1.4) 0
Single lobe 1 (0.4) 0
Bilateral–liver 5 (1.8) 0
Mean duration of mechanical ventilation (days) 5 (IQR 2–14) 2 (IQR 1–4)
Stay in ICU (days) 7 (IQR 4–17) 3 (IQR 2–5)
ECMO support after transplantation 27 (9.7) 20 (2.8)
Primary graft dysfunction 62 (22.4) 160 (22.7)
Hospital mortality 46 (16.6) 50 (7.1)
Values in parentheses are percentages unless specified  IQR interquartile range  ICU intensive care unit
ECMO extracorporeal membrane oxygenation
FIG 3. Kaplan–Meier survival by diagnosis for adult lung
transplantation (1994–2004) (Reproduced with permission from
Elsevier Limited)
FIG 2. Kaplan–Meier survival by era for adult lung transplantation
(1988–2005) (Reproduced with permission from Elsevier
Limited)
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her life. The cost of immunosuppression, depending upon the
regimen used, is about US$ 1500–2000 per month (see Table III).
In the USA, Medicare Part B covers 80% of the cost after an
annual deductible charge of US$ 100 and the remaining 20% of
the cost is either out-of-pocket or patients can have supplemental
insurance for the same.
LONG TERM RESULTS
The benchmark survival rates for lung transplants are 87% at
3 months, 78% at 1 year, 62% at 3 years, 50% at 5 years and
26% at 10 years. Mortality is highest in the first year following
transplantation. In the first 30 days following transplant, primary
graft dysfunction is the most important cause of morbidity and
accounts for the majority of deaths. Beyond that, infectious
complications continue to be a cause of morbidity and mortality
for up to a year. Chronic rejection, also known as bronchiolitis
obliterans syndrome (BOS), remains the Achilles’ heel of lung
transplant survivors and is the foremost long term cause of death.
Almost 50% of patients will have some degree of BOS by 5
years.21 However, long term survival is improving over the past 2
decades among various working groups (Fig. 4).
Despite potential post-transplant complications, the procedure
significantly improves the quality of life of recipients. More than
80% of post-transplant patients have no activity limitations; this
benefit in survivors is seen even beyond 10 years. About 50% of
3-year survivors report that they have returned to either part-time
or full-time work (Fig. 5).21
EARLY COMPLICATIONS
Acute rejection
Acute allograft rejection is one of the most common complications
following lung transplantation. Data from several large series
document that only 8%–24% of recipients escape rejection in the
first year following transplantation.30,31 The importance of acute
rejection lies in the fact that it is an important predictor of
development of chronic rejection. The Lung Rejection Study
Group (LRSG) has classified acute rejection into 2 components
based on histological findings:
1. Perivascular inflammation, which is graded as follows: A0 (no
rejection), A1 (minimal), A2 (mild), A3 (moderate) and A4
(severe).
2. Airway inflammation, which is graded as follows: BX
(unknown), B0 (none), B1 (minimal), B2 (mild), B3 (moderate)
and B4 (severe).
To date, no predictors for the development of acute rejection
have been delineated. Induction therapy in the form of interleukin-
2 receptor blocker or antithymocyte globulin has been shown to
reduce the incidence of acute rejection.32,33
Clinically, rejection presents as an upper respiratory tract
infection with symptoms of cough, dyspnoea, low grade fever and
fatigue. The diagnosis is usually made on transbronchial
surveillance bronchoscopy and biopsy. Currently, all rejection
graded A2 and above are treated with a pulse of steroids and an
alteration in the maintenance therapy. Confirmation of resolution
of the acute rejection with a follow up biopsy after 4–6 weeks is
important due to its significant contribution to the pathogenesis of
chronic rejection.
Primary graft dysfunction
Primary graft dysfunction is a form of acute lung injury that
complicates lung transplantation. It remains the most important
TABLE III. Monthly expenditure on immunosuppressive drugs
Drug Number Cost (US$)
Neoral, gengraf, 25 mg 180 caps 295
Neoral, gengraf, 100 mg 180 caps 1160
or
Tacrolimus, 1 mg 200 caps 295
Tacrolimus, 5 mg 60 caps 1061
or
Sirolimus, 1 mg (not used frequently) 30 tabs 243
150 tabs 1188
and
Mycophenolate mofetil, 500 mg 120 caps 746
180 caps 1115
and
Prednisone, 5 mg 120 tabs 10
cause of morbidity and mortality in the early postoperative period
following transplantation. Poor oxygenation, decreased lung
compliance, interstitial oedema, elevated pulmonary vascular resis-
tance and pulmonary infiltrates on chest X-ray are the characteristic
clinical features of this condition. Patients remain ventilated for
a prolonged period of time and in severe cases require extracorpo-
real membrane oxygenation (ECMO) support.34 Treatment options
include ventilatory support, diuresis, pulmonary vasodilatation,
ECMO and urgent re-transplantation in severe cases.
Airway anastomotic complications
Before the era of cyclosporin, airway complications were a major
cause of mortality following lung transplantation. The bronchial
arteries are not re-constituted during implantation and the donor
FIG 4. Employment status of survivors following lung transplantation
(Reproduced with permission from Elsevier Limited)
Working (FT/PT
Status unknown)
Working Part Time
Working Full Time
Retired
Not Working
1 year
(N=7,327)
3 years
(N=4,443)
5 years
(N=2,648)
10 years
(N=507)
FIG 5. Functional status of survivors following lung transplantation
(Reproduced with permission from Elsevier Limited)
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(N=6,596)
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(N=4,176)
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(N=398)
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bronchus has to rely on the pulmonary circulation in the early days
following surgery. Post-transplantation pulmonary parenchymal
pathology decreases this collateral flow and renders the donor
bronchus ischaemic which leads to anastomotic complications.
The incidence of airway complications that require intervention is
about 10% in the modern era. Airway complications increase the
cost associated with transplant and decrease the quality of life but
do not appear to affect survival.
LATE COMPLICATIONS
Chronic rejection/bronchiolitis obliterans syndrome (BOS)
BOS is the major cause of late morbidity and mortality following
lung transplantation. It is characterized by a progressive decline
in graft function with an obstructive physiology. Clinically, it
presents as a decline in FEV1 from the baseline. It is a diagnosis
of exclusion after all other causes of decreased lung function have
been eliminated. Histologically, BOS is characterized by fibrous
obliteration of the respiratory bronchioles. It affects almost 50%
of lung transplant recipients by 3 years and remains the leading
cause of late death following transplantation. The median time to
diagnosis for BOS is 4.3 years in adult recipients. The pathogenesis
of BOS is believed to be multifactorial and treatment usually
involves alteration of immunosuppression or re-transplantation in
selected cases. Table IV shows the classification of BOS.
IS IT WORTH IT?
While there is no doubt that lung transplantation improves the
quality of life among its recipients, questions about the pro-
cedure’s cost-effectiveness remain unanswered. It is estimated
that, on an average, lung transplantation would cost approximately
US$ 200 000–250 000, not including preoperative evaluation and
follow up care.35 The cost varies widely, both from centre to centre
and with the diagnosis of the recipient. Liver transplants in India
are about 20% as expensive as in western countries,36 and we
would anticipate that lung transplants in India would also entail
reduced cost. Cost-effectiveness research to date has attempted to
balance financial data with findings regarding both quality of life
and costs of care for patients who do not undergo transplant for
chronic end-stage lung diseases and, while the jury is still out, there
is evidence of cost-effectiveness for certain subsets of patients
who undergo lung transplantation.37–39
THE BARE ESSENTIALS TO START A LUNG
TRANSPLANT PROGRAMME
In this age of outcomes-driven and cost-effective medicine,
starting a lung transplant programme can be a challenging and
daunting task. Besides the need for adequately trained and dedicated
personnel experienced in lung transplantation, the key to success
is the need for administrative and financial support from the res-
pective institution/government in the early phases of development
of the programme. The personnel absolutely necessary to start
up a programme include at least 2 trained surgeons capable of
performing all aspects of lung transplantation, a team of trained
cardiothoracic anaesthesiologists and one (preferably 2) transplant
pulmonologist(s). Other important members of the team include
a transplant nurse coordinator(s), social worker, clinical psycho-
logist, transplant pharmacist and a financial manager. The
institution should have a dedicated perfusion team capable of
providing not only cardiopulmonary bypass support in the operating
room but also ECMO, if necessary in the postoperative period.
The education of the nursing staff and physicians who will be
involved in the care of these patients in the intensive care unit and
wards cannot be overemphasized. Finally, the institution must
have the basic infrastructure and support in terms of blood bank,
histocompatibility leukocyte antigen (HLA) laboratory, clinical
laboratory capable of monitoring immunosuppressive drug levels,
endoscopy suites, pulmonary function laboratory and physical
therapy.
THE FUTURE
The founding of the Indian Society of Organ Transplantation in
the 1980s (www.isot2007.org), and the subsequent passing of the
Transplantation of Human Organs Act (Act No. 42 of 1994) by the
Indian Government, were important steps in the implementation
of a countrywide solid organ transplantation programme. This has
translated into the development of some successful liver, kidney
and other organ transplant/organ-sharing networks across India.36,40
Other developments have included the initiation of the Multi
Organ Harvesting Aid Network (www.MOHANfoundation.org)
in 1997, Organ Retrival and Banking Organization
(www.aiims.edu/aims/orbo) and the Indian Transplant Registry
(www.transplantindia.com) in 2005. These physician/patient
partnerships have made progress in their goal (according to
MOHAN’s mission statement) to ‘popularize the cause of organ
donation’ by distributing donor cards and educational materials
about organ donation, and by providing patients with transplant
programme information and support.
Despite diligent efforts of activists in the transplant community,
there remains a need for a central regulatory organization similar
to the non-profit scientific and educational United Network of
Organ Sharing (www.unos.org), which administers the organ
procurement and transplantation network in the USA. Such an
organization would enhance infrastructure to increase organ
donation and procurement. Another important aspect of
successfully developing organ transplantation in India lies in the
education of its masses about the importance of donating organs.
There is passionate debate in India about spending money on
newer procedures and technology compared with spending money
on preventive healthcare. Experience in the USA has shown that
the costs of lung transplantation are outweighed by the long term
benefits. In India, in the field of transplantation, healthcare policy
leaders have shown foresight in future planning. The central
Ministry of Health and Family Welfare has already sanctioned
Rs 600 crore to start 6 tertiary healthcare centres with transplant
facilities in India by 2013. These facilities will be similar to the
one at the All India Institute of Medical Sciences (AIIMS). The
goal is to have at least one transplant centre in every state by the
year 2020. Even private institutions such as the Global Hospitals
Group are investing Rs 700 crore to set up transplant facilities in
cities such as Chennai, Delhi, Kolkata and Mumbai. Organ
transplantation in India is heading in a positive direction although
it may not be at the pace that patients and physicians would like
but the time may be right to consider lung transplant as a treatment
option for end-stage lung diseases in India.
TABLE IV. Classification of the bronchiolitis obliterans syndrome
(BOS)
Class Criteria
0 FEV1 >90% of baseline and FEF25%–75% >75% of baseline
0–P FEV1 81%–90% of baseline and FEF25%–75% <75% of baseline
1 FEV1 66%–80% of baseline
2 FEV1 52%–65% of baseline
3 FEV1 <50% of baseline
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